Toward new legislation on drugs in Europe

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedures suggested by the european Community regulations seem to hamper achievement of the real aims. The scientific community needs to identify the problems and propose and debate solutions with the politicians concerned, so that the european regulatory authority can fulfill its commitment to the defense of public health. The European Commission has made its proposal for improving the system. Here are our first comments.

Original languageEnglish
Pages (from-to)51-56
Number of pages6
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume2
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Drug Legislation
European Union
Public Health

Keywords

  • European Community legislation on drugs
  • Marketing authorization procedures
  • Pharmaceutical regulation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology

Cite this

Toward new legislation on drugs in Europe. / Garattini, Silvio; Bertele, Vittorio.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 2, No. 1, 2002, p. 51-56.

Research output: Contribution to journalArticle

@article{e04de04e50eb4cbba173937cec2f0f77,
title = "Toward new legislation on drugs in Europe",
abstract = "Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedures suggested by the european Community regulations seem to hamper achievement of the real aims. The scientific community needs to identify the problems and propose and debate solutions with the politicians concerned, so that the european regulatory authority can fulfill its commitment to the defense of public health. The European Commission has made its proposal for improving the system. Here are our first comments.",
keywords = "European Community legislation on drugs, Marketing authorization procedures, Pharmaceutical regulation",
author = "Silvio Garattini and Vittorio Bertele",
year = "2002",
doi = "10.1586/14737167.2.1.51",
language = "English",
volume = "2",
pages = "51--56",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Toward new legislation on drugs in Europe

AU - Garattini, Silvio

AU - Bertele, Vittorio

PY - 2002

Y1 - 2002

N2 - Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedures suggested by the european Community regulations seem to hamper achievement of the real aims. The scientific community needs to identify the problems and propose and debate solutions with the politicians concerned, so that the european regulatory authority can fulfill its commitment to the defense of public health. The European Commission has made its proposal for improving the system. Here are our first comments.

AB - Everybody acknowledges the merits of the European Medicines Evaluation Agency and the progress the European system has permitted in evaluating and approving medicinal products. Nevertheless, the system established in 1995 is ripe for updating and improvement in the light of experience. Some limitations of the procedures suggested by the european Community regulations seem to hamper achievement of the real aims. The scientific community needs to identify the problems and propose and debate solutions with the politicians concerned, so that the european regulatory authority can fulfill its commitment to the defense of public health. The European Commission has made its proposal for improving the system. Here are our first comments.

KW - European Community legislation on drugs

KW - Marketing authorization procedures

KW - Pharmaceutical regulation

UR - http://www.scopus.com/inward/record.url?scp=0036073709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036073709&partnerID=8YFLogxK

U2 - 10.1586/14737167.2.1.51

DO - 10.1586/14737167.2.1.51

M3 - Article

C2 - 19807430

AN - SCOPUS:0036073709

VL - 2

SP - 51

EP - 56

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -